Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differential Consequences of Tramadol in Overdosing: Dilemma of a Polymorphic Cytochrome P450 2D6-Mediated Substrate.

Journal of pain & palliative care pharmacotherapy - 1 Sept 2015

Srinivas Nuggehally R

Abstract excerpt

Tramadol is a centrally acting opioid analgesic that is prone to polymorphic metabolism via cytochrome P450 (CYP) 2D6. The generation of the active metabolite, O-desmethyltramadol, which occurs through the CYP 2D6 pathway, significantly contributes to the drug's activity. However, dosage adjustments of tramadol are typically not practiced in the clinic when treating patients who are homozygous extensive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Analgesics, Opioid
Share to Cytochrome P-450 CYP2D6
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phenotype

Source

Identifiers

PMID: 26367475
DOI: 10.3109/15360288.2015.1047555

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differential Consequences of Tramadol in Overdosing: Dilemma of a Polymorphic Cytochrome P450 2D6-Mediated Substrate.PMID 26367475Read ↗

Assessment of tramadol pharmacokinetics in correlation with CYP2D6 and clinical symptoms.Semantic proximity Read ↗

Influence of CYP2D6 phenotype on the pharmacokinetics and pharmacodynamics of tramadol in patients treated for post-operative pain management.Semantic proximity Read ↗

Miotic action of tramadol is determined by CYP2D6 genotype.Semantic proximity Read ↗

Trends in Tramadol: Pharmacology, Metabolism, and Misuse.Semantic proximity Read ↗

Near-fatal tramadol cardiotoxicity in a CYP2D6 ultrarapid metabolizer.Semantic proximity Read ↗

Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes.Semantic proximity Read ↗

Metabolic ratios and SNPs implicated in tramadol-related deaths.Semantic proximity Read ↗

Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype.Semantic proximity Read ↗

Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of CYP2D6, CYP2B6, and CYP3A4 genotype.Semantic proximity Read ↗

Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study.Semantic proximity Read ↗

Physiologically based pharmacokinetic modeling of tramadol to inform dose adjustment and drug-drug interactions according to CYP2D6 phenotypes.Semantic proximity Read ↗

Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.